Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Vicarious Surgical Inc. (RBOT) reported an insider transaction by a reporting person who is a director, president, and 10% owner. On 11/20/2025, the insider sold 816 shares of Class A common stock in a transaction coded “S”. The weighted average sale price was $2.715 per share, with individual trade prices ranging from $2.54 to $2.94 per share.
The filing explains that the sale was executed solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on May 19, 2022, under the company’s equity incentive plan, and was not a discretionary trade. After this transaction, the insider beneficially owned 48,348 shares of Class A common stock.
Vicarious Surgical Inc. (RBOT) insider Sammy Khalifa has filed a Form 144 notice to sell 653 shares of Class A common stock through UBS Financial Services on the NYSE, with an aggregate market value of 1,834.93. The filing shows 5,894,273 Class A shares outstanding. The shares to be sold were acquired on 11/19/2025 through a restricted stock lapse transaction for 1,902 shares, with payment also described as a restricted stock lapse.
The notice also reports prior sales by the same seller over the past three months: 653 shares sold on 08/20/2025 for gross proceeds of 3,801 and 239 shares sold on 09/03/2025 for gross proceeds of 1,293. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Vicarious Surgical’s current or prospective operations.
Vicarious Surgical Inc. (RBOT) insider Adam Sachs filed a notice to sell Class A common stock under Rule 144. The filing reports a proposed sale of 816 shares through UBS Financial Services Inc. on the NYSE, with an aggregate market value of $2,292.96. Shares outstanding were 5,894,273 at the time referenced, giving context for the relative size of the transaction. The shares to be sold came from a restricted stock lapse on 11/19/2025, when 2,377 shares of Class A common stock were acquired.
The filing also lists sales by the same seller during the prior three months, including 817 shares sold on 08/20/2025 and 463 shares sold on 09/03/2025. By signing the notice, the seller represents that he is not aware of any material adverse, nonpublic information about the company’s current or future operations.
Vicarious Surgical Inc. filed a Form S-3 to register the resale of up to 2,300,000 shares of Class A common stock. These shares are issuable upon exercise of Series A and Series B common warrants previously sold in an October 2025 private placement.
The company is not selling any shares in this registration and will receive no proceeds from resales; it would receive cash only if holders exercise warrants, which have a $5.10 exercise price and become exercisable upon required stockholder approval. Beneficial ownership caps limit exercises to 4.99% (or 9.99% if elected). Shares outstanding were 5,894,273 as of November 12, 2025. RBOT last traded at $4.57 on November 11, 2025.
Vicarious Surgical (RBOT) filed its Q3 2025 10‑Q and flagged liquidity risk. The company reported a Q3 net loss of $11,058,000, with total operating expenses of $11,503,000 (down 35% year over year). For the nine months ended September 30, 2025, net loss was $39,667,000 and net cash used in operating activities was $35,764,000.
Cash, cash equivalents and short‑term investments were $13,414,000 as of September 30, 2025. The company received approximately $5,200,000 in net proceeds from an October 2025 registered direct offering. Management states this raises substantial doubt about continuing as a going concern and currently expects resources to support operations into the first quarter of 2026.
The company remains pre‑revenue and continues R&D on its single‑port surgical robot, noting controlled builds in April 2025 and August 2025. Vicarious also disclosed prior NYSE noncompliance with the $50,000,000 market cap/equity standard; the exchange accepted its remediation plan, and the stock continues to trade during the cure period.
Vicarious Surgical Inc. furnished an 8‑K announcing its results for the third quarter ended September 30, 2025, along with a business update. The company provided the details via a press release furnished as Exhibit 99.1.
The company noted that the information in this report, including Exhibit 99.1, is being furnished and is not deemed filed under Section 18 of the Exchange Act or incorporated by reference unless expressly stated.
Vicarious Surgical Inc. (RBOT) filed a Form D reporting a private placement under Rule 506(b) with a Total Amount Sold of $11,730,000 and Total Remaining $0. The filing notes the total offering amount reflects gross proceeds assuming cash exercise of all warrants issued in the private placement.
The securities include equity, warrants or other rights to acquire securities, and securities to be acquired upon exercise. The Date of First Sale was 2025-10-09. Lake Street Capital Markets, LLC acted as placement agent, receiving a 6.0% cash fee on gross proceeds plus $100,000 expense reimbursement.
The company indicates proceeds are for working capital; while none are specifically set aside for officers or directors, some working capital may indirectly cover executive salaries and director stipends. Industry is listed as Health Care — Biotechnology, and issuer size was marked “Decline to Disclose.”
Vicarious Surgical Inc. entered into a securities purchase agreement for a capital raise using a registered direct offering and a concurrent private placement. The company will sell 588,300 shares of Class A common stock and pre-funded warrants to purchase up to 561,700 additional shares, together with Series A and Series B common warrants to purchase a total of 2,300,000 shares, all at an exercise price of $5.10 per share for the common warrants. Vicarious Surgical expects to receive approximately $5.9 million in gross proceeds before fees and expenses.
The pre-funded warrants are immediately exercisable at $0.0001 per share and are subject to a 9.99% beneficial ownership cap. The common warrants become exercisable after stockholder approval and include ownership limits of 4.99% or, at the holder’s election, 9.99%, as well as adjustment and fundamental transaction protections. The company agreed to short-term restrictions on issuing additional equity and on variable rate transactions, and its officers and directors will be subject to a 30-day lock-up.
Vicarious Surgical Inc. is offering Class A common stock at $5.10 per share and Pre-Funded Warrants at $5.0999 each, with purchasers reimbursing a placement agent for up to $100,000 of offering expenses. The base offering is 5,305,724 shares and would reach 6,455,724 shares assuming full exercise of the Pre-Funded Warrants. After the offering (assuming no exercise of Pre-Funded Warrants), Class A stock would represent 90.0% of issued share capital and 31.1% of combined voting power; Class B would represent 10.0% of issued share capital and 68.9% of combined voting power.
Reported per-share net tangible book value before the offering is $3.8773, increasing by $0.1026 to an as-adjusted $3.9799, with dilution to new investors of $1.1201. The Pre-Funded Warrants will not be listed, limiting their liquidity. A concurrent private placement includes Series A and Series B Common Warrants to purchase 1,150,000 shares each at an exercise price of $5.10.
Risk disclosures highlight barriers in the surgical robotics market: legacy systems have limited capabilities, are difficult to use, show low utilization, and carry significant capital investment costs—estimated up to $2.0M per system plus 10-20% annual service.
Vicarious Surgical Inc. (RBOT) director Joseph Edward Doherty was granted a stock option on 06/27/2025 to buy 8,003 shares of Class A common stock at an exercise price of $7.61 per share. After the grant, the reporting person beneficially owns 8,003 shares tied to this option on a direct basis.
The option's underlying shares will vest on 06/27/2026 or one day prior to the issuer's next annual meeting of shareholders, whichever is earlier, subject to the reporting person's continued service. The Form 4 was signed by an attorney-in-fact on 10/02/2025.